Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090144 | 0.86 | ADORA2A (0.76) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5022651 | 0.80 | ADORA1 (0.69) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL6038184 | 0.79 | ADORA3 (0.75) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5016122 | 0.79 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5024967 | 0.79 | ADORA3 (0.75) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL13920230 | 0.79 | ADORA3 (0.75) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5017648 | 0.78 | ADORA2A (0.65) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5017646 | 0.78 | ADORA2A (0.80) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5017710 | 0.78 | ADORA2A (0.73) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5017739 | 0.77 | ADORA2A (0.64) | ADORA1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | ADORA1 3/4885ADORA3 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.